Richard S Lindahl insider trades

Open-market stock purchases and sales by Richard S Lindahl, EVP, Chief Financial Officer at Emergent BioSolutions Inc, from SEC Form 4 filings since Mar 31, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -83%.

Recent trades

DateStockTradeValue
Jun 8, 2026EBS Emergent BioSolutions IncSold (not open market)$31.7K
Apr 29, 2026EBS Emergent BioSolutions IncBought (not open market)—
Mar 5, 2026EBS Emergent BioSolutions IncSold (not open market)$200K
Mar 3, 2026EBS Emergent BioSolutions IncBought (not open market)—
Mar 1, 2026EBS Emergent BioSolutions IncSold (not open market)$5.6K
Feb 25, 2026EBS Emergent BioSolutions IncSold (not open market)—
Feb 6, 2026EBS Emergent BioSolutions IncSold (not open market)$61.6K
Feb 6, 2026EBS Emergent BioSolutions IncSold (not open market)$504K
Jan 2, 2026CMPX Compass Therapeutics, IncBought (not open market)—

Companies traded

  • EBS Emergent BioSolutions Inc: 1 buy, last Jun 8, 2026
  • CMPX Compass Therapeutics, Inc: other filings, last Jan 2, 2026
  • CEB CEB Inc: 2 sales, last Apr 5, 2017
  • EXBD Corporate Executive Board Co: 1 buy, last Nov 20, 2012

Get free alerts when Richard S Lindahl files a new trade →